Coagulation markers in diagnostic and monitoring of thromboembolic complication in COVID-19

Obrazek miniatury
Data
2021
Autorzy
Czarnecka-Czapczyńska, Magdalena
Bartusik-Aebisher, Dorota
Krupka-Olek, Magdalena
Aebisher, David
Cieślar, Grzegorz
Latos, Wojciech
Kawczyk-Krupka, Aleksandra
Tytuł czasopisma
ISSN
Tytuł tomu
Wydawnictwo
Wydawnictwo Uniwersytetu Rzeszowskiego
Abstrakt
Introduction. Coronavirus disease 2019 (COVID-19) was first observed in China in Wuhan city, Hubei province in December, 2019, and specified as a pandemic by the World Health Organization (WHO). COVID-19 is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2). Aim. The aim of this article is to discuss epidemiology of thromboembolic complication in COVID-19. Material and methods. This article is a review done in regards to discuss clinical features of the anticoagulation treatment in COVID-19. Analysis of the literature. A review is discussed an anticoagulation treatment in 41 manuscripts. Conclusion. Most commonly coagulation abnormalities in patient with COVID-19 is mild thrombocytopenia. Apart from their typical role in thrombosis and hemostasis, platelets mediate key aspects of immune and inflammatory.
Opis
Słowa kluczowe
anticoagulation , coagulation abnormalities , COVID-19
Cytowanie
European Journal of Clinical and Experimental Medicine T. 19, z. 3 (2021), s. 241–245